5 Most Promising Penny Stocks According to Analysts

3. aTyr Pharma, Inc. (NASDAQ:LIFE)

Average Analyst Price Estimate: $23.00

Upside Potential: 1067.51%

According to Yahoo Finance, aTyr Pharma, Inc. (NASDAQ:LIFE)’s average price estimate according to Wall Street analysts is $21.3. TipRanks’ stock screener also shows that aTyr Pharma, Inc. (NASDAQ:LIFE)’s average price estimate is $23. aTyr Pharma, Inc. (NASDAQ:LIFE)’s lead therapeutic candidate is efzofitimod, which is a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis.

As of the end of the first quarter of 2023, 8 hedge funds in Insider Monkey’s database of 943 hedge funds reported having stakes in aTyr Pharma, Inc. (NASDAQ:LIFE). The most significant stakeholder of aTyr Pharma, Inc. (NASDAQ:LIFE) during this period was Timothy P. Lynch’s Stonepine Capital which owns a $10.13 million stake in the company.